Core Viewpoint - A securities class action lawsuit has been filed against Sable Offshore Corp. for failing to disclose material information during the class period, which has led to a decline in the company's stock price [3][4]. Group 1: Lawsuit Details - Investors who purchased Sable Offshore securities between May 19, 2025, and June 3, 2025, or through the company's secondary public offering on May 21, 2025, have until September 26, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Central District of California, under the case name Johnson v. Sable Offshore Corp., et al., No. 25-cv-6869 [5]. Group 2: Impact on Stock Price - Following the disclosure of a temporary restraining order that prohibits Sable Offshore from restarting oil transportation through the Las Flores Pipeline System, the company's stock price fell by $0.94, or 3.91%, closing at $23.10 on June 4, 2025 [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case. The firm has been recognized among the top 10 firms nationally based on total settlement value [5].

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for allegedly making false and misleading statements regarding its oil production activities off the coast of California during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit covers purchasers of Sable Offshore Corp. securities between May 19, 2025, and June 3, 2025, and those involved in the company's secondary public offering on May 21, 2025 [1]. - Defendants are accused of falsely claiming that Sable Offshore Corp. had restarted oil production when it had not, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors in this case [4]. - The firm encourages affected investors to join the lawsuit and provide any information that may assist in the investigation [5].

If you purchased or acquired securities in Flywire between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Flywire Corporation ("Flywire" or the "Company") (NASDAQ:FLYW) in the United States ...

Core Viewpoint - The J.M. Smucker Company is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results and significant impairment charges related to its Sweet Baked Snacks segment and the Hostess Brands acquisition [1][3][4]. Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3]. - For Q3 2025, Smucker reported an 8% decrease in comparable net sales in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3]. - In Q4 2025, the company experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, incurring an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [4]. - Following the Q4 results, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share [4]. Strategic Implications - The company has revised its 2026 financial plan to account for the sustained underperformance of the Sweet Baked Snacks segment, contradicting previous assurances about synergies driving sustainable growth [4].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure - On July 18, 2025, Barnes & Noble disclosed that there may be an overstatement of up to $23.0 million in its accounts receivable balance as of the fiscal year-end on May 3, 2025, due to issues related to the recording of digital sales costs [3]. - Following this disclosure, Barnes & Noble's share price fell by $2.36, or approximately 21%, closing at $8.87 per share on July 21, 2025 [3]. Legal Context - The investigation by Kirby McInerney LLP focuses on whether Barnes & Noble and/or its officers have engaged in unlawful business practices that could affect shareholders [1][4]. - The law firm specializes in securities litigation and has a history of recovering billions of dollars for shareholders [6].

Core Points - Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited complied with federal securities laws following a subpoena from the U.S. Securities and Exchange Commission regarding the company's disclosures on prostate cancer therapeutic candidates [1] - The announcement of the subpoena led to a decline in Telix's stock price [1] Company Information - Telix Pharmaceuticals Limited is publicly traded on NASDAQ under the ticker TLX [1] - The company is involved in the development of therapeutic candidates for prostate cancer [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [2][4]. Group 1: Legal Investigation and Class Action - Investors who suffered losses exceeding $50,000 in Alto are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - A federal securities class action has been filed against Alto, with a deadline of September 19, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Alto - The complaint alleges that Alto and its executives violated federal securities laws by making false statements and failing to disclose critical information about ALTO-100's effectiveness [4]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical and commercial prospects [4]. Group 3: Stock Performance Impact - Following the announcement of ALTO-100's Phase 2b trial results, which did not meet its primary endpoint, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [5]. - Analysts reacted by adjusting their price targets, with Jeffries reducing its target for Alto from $33 to $17, citing concerns over the company's biomarker approach [6].

Core Viewpoint - Neogen Corporation is facing a securities class action lawsuit for failing to disclose material information during the class period from January 5, 2023, to June 3, 2025, which has led to significant financial losses for investors [1][3]. Company Performance - On April 9, 2025, Neogen reported a quarterly revenue decrease of 3.4% to $221 million, attributed to integration issues, and lowered its FY25 guidance, anticipating capital expenditures of $100 million due to reduced adjusted EBITDA and integration-related costs [4]. - Following the revenue report, Neogen's share price dropped 28% to close at $5.02 per share on a volume of 47 million shares [4]. - On June 4, 2025, the company projected an EBITDA margin in the high-teens, a significant decline from the previous quarter's profit margin of 22%, resulting in an additional 17% drop in share price to close at $4.96 per share [4]. Legal Context - The lawsuit is titled Operating Eng'rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802, and is pending in the United States District Court for the Western District of Michigan [5]. - Investors who purchased shares during the class period have until September 16, 2025, to file lead plaintiff applications [1][2].

Core Points - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] - The lawsuit claims that Capricor made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3] - Following the CRL announcement, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [4] Company Information - Capricor Therapeutics is involved in developing cell therapies, specifically targeting conditions like cardiomyopathy associated with DMD [2] - The company faced significant challenges with the FDA regarding its lead drug candidate, deramiocel, which has implications for its future development and market potential [3] Legal Context - The class action lawsuit allows investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, to seek recovery for losses incurred due to the alleged misleading statements [1][4] - Investors have until September 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]

Core Points - Holzer & Holzer, LLC is investigating Capricor Therapeutics, Inc. for potential compliance issues with federal securities laws following the receipt of a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel [1] - The announcement of the CRL led to a decline in Capricor's stock price [1] Company Information - Capricor Therapeutics, Inc. trades on NASDAQ under the ticker CAPR [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]